Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antipsychotic Drugs: Typical and Atypical Agents

Antipsychotic Drugs: Typical and Atypical Agents

Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...

Psychosis: Goals of Pharmacotherapy

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.

Psychosis and Antipsychotic Drugs: Overview

Psychosis and Antipsychotic Drugs: Overview

The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...

Antiepileptic Drugs: Potassium Channel Activators

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...

Antipsychotic Drugs: Therapeutic Uses and Side Effects

Antipsychotic Drugs: Therapeutic Uses and Side Effects

Antipsychotic drugs primarily block dopamine and serotonin receptors and cholinergic, adrenergic, and histaminergic receptors, thereby reducing hallucinations and delusions in conditions like schizophrenia. However, they can trigger unwanted extrapyramidal effects such as dystonias, Parkinson-like symptoms, and tardive dyskinesia.
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...

Drug Therapy

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Advanced maternal age and assisted reproductive technologies: outcomes, genomics, and real-world evidence.

Frontiers in reproductive health·2026

Same author

Suicidal Behaviour Prior to First Episode Psychosis: Wider and More Widespread Grey-Matter Alterations.

Archives of suicide research : official journal of the International Academy for Suicide Research·2025

Same author

The role of childhood maltreatment and mental health disorders on suicidal behaviour in adolescents.

Child abuse & neglect·2024

Same author

The mediating role of reflective functioning in the association between childhood trauma and suicide attempt.

Journal of psychiatric research·2024

Same author

Pattern of long-term weight and metabolic changes after a first episode of psychosis: Results from a 10-year prospective follow-up of the PAFIP program for early intervention in psychosis cohort.

European psychiatry : the journal of the Association of European Psychiatrists·2022

Same author

Association and epistatic analysis of white matter related genes across the continuum schizophrenia and autism spectrum disorders: The joint effect of NRG1-ErbB genes.

The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry·2021

Search research articles

Related Experiment Video

Updated: Jun 25, 2025

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

Aripiprazole as protector against COVID-19 mortality.

C Loucera-Muñecas^1,2, M Canal-Rivero^3,4,5, M Ruiz-Veguilla^6,7,8,9

¹Computational Medicine Platform, Andalusian Public Foundation Progress and Health-FPS, Seville, Spain.

Scientific Reports

|May 29, 2024

Summary

Antipsychotic use in COVID-19 patients is debated. This study found aripiprazole significantly decreased the risk of death in inpatients with Coronavirus Disease 19 (COVID-19).

Keywords:

Antipsychotics COVID-19 Mortality SARS-CoV-2

More Related Videos

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

Related Experiment Videos

Last Updated: Jun 25, 2025

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

Area of Science:

Pharmacology
Infectious Diseases
Epidemiology

Background:

The relationship between antipsychotic medications and severe Coronavirus Disease 19 (COVID-19) outcomes remains controversial.
Previous studies have yielded conflicting results regarding the potential adverse or protective effects of antipsychotics in COVID-19 patients.

Purpose of the Study:

To investigate whether antipsychotics influence the risk of fatal outcomes in patients diagnosed with COVID-19.
To determine if specific antipsychotic medications offer protective effects against COVID-19 mortality.

Main Methods:

A population-based retrospective cohort study was conducted using data from January 2020 to November 2020.
Inclusion criteria involved laboratory-confirmed COVID-19 inpatients aged 18 years or older (n=15,968).
Two sub-cohorts (n=2536) were analyzed: those with no prior medication and those prescribed antipsychotics within 15 days of hospitalization. Survival and odds ratio analyses were performed.

Main Results:

Among eight antipsychotics studied, only aripiprazole demonstrated a statistically significant reduction in the risk of death from COVID-19.
The adjusted odds ratio (OR) for mortality with aripiprazole was 0.86 (95% CI, 0.79-0.93), with a multiple-testing adjusted p-value < 0.05.
These findings remained consistent across both unadjusted and covariate-adjusted analyses, indicating a robust association.

Conclusions:

Aripiprazole appears to have a distinct beneficial effect in protecting COVID-19 infected individuals from fatal clinical outcomes.
The study speculates that aripiprazole's potential to modulate immunological pathways and inflammatory enzymes critical in COVID-19 pathogenesis may underlie these protective effects.